CA2532302C - Method for the preparation of controlled release formulations - Google Patents

Method for the preparation of controlled release formulations Download PDF

Info

Publication number
CA2532302C
CA2532302C CA2532302A CA2532302A CA2532302C CA 2532302 C CA2532302 C CA 2532302C CA 2532302 A CA2532302 A CA 2532302A CA 2532302 A CA2532302 A CA 2532302A CA 2532302 C CA2532302 C CA 2532302C
Authority
CA
Canada
Prior art keywords
poly
organic
agent
organic phase
bioactive agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2532302A
Other languages
English (en)
French (fr)
Other versions
CA2532302A1 (en
Inventor
P. Cook Gary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evonik Corp
Original Assignee
Evonik Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Corp filed Critical Evonik Corp
Publication of CA2532302A1 publication Critical patent/CA2532302A1/en
Application granted granted Critical
Publication of CA2532302C publication Critical patent/CA2532302C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2532302A 2003-07-15 2004-07-15 Method for the preparation of controlled release formulations Expired - Fee Related CA2532302C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48766303P 2003-07-15 2003-07-15
US60/487,663 2003-07-15
PCT/US2004/022816 WO2005009356A2 (en) 2003-07-15 2004-07-15 Method for the preparation of controlled release formulations

Publications (2)

Publication Number Publication Date
CA2532302A1 CA2532302A1 (en) 2005-02-03
CA2532302C true CA2532302C (en) 2016-12-20

Family

ID=34102710

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2532302A Expired - Fee Related CA2532302C (en) 2003-07-15 2004-07-15 Method for the preparation of controlled release formulations

Country Status (9)

Country Link
US (1) US8871269B2 (enExample)
EP (2) EP2462896A1 (enExample)
JP (2) JP5165239B2 (enExample)
CN (2) CN1852687B (enExample)
AU (1) AU2004259208B2 (enExample)
BR (1) BRPI0412059A (enExample)
CA (1) CA2532302C (enExample)
ES (1) ES2625343T3 (enExample)
WO (1) WO2005009356A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
WO2005003180A2 (en) 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
AU2004259208B2 (en) 2003-07-15 2011-04-28 Evonik Corporation Method for the preparation of controlled release formulations
EP1660039B1 (en) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
AU2004259209A1 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
CA2552241C (en) * 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US20100290982A1 (en) * 2007-04-13 2010-11-18 University Of North Texas Health Science Center At Fort Worth Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
AU2008240155B2 (en) * 2007-04-13 2012-09-20 University Of North Texas Health Science Center At Fort Worth Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics
WO2008130158A1 (en) * 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
GB0709322D0 (en) * 2007-05-15 2007-06-20 Nordic Bioscience As Exposure agent for detection of vitamin d
WO2008145183A1 (en) * 2007-05-30 2008-12-04 Nestec S.A. Oil-in-water emulsion and its use for the delayed release of active elements
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
ES2324009B1 (es) * 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US9161943B2 (en) * 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2009100222A1 (en) * 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
BR112012002709A2 (pt) * 2009-08-05 2019-04-30 Pieris Ag formulações de liberação controlada de muteínas de lipocalina
US20110151028A1 (en) * 2009-12-19 2011-06-23 Filiberto Zadini Topical vaginal preparation
ES2362604B1 (es) * 2009-12-22 2012-06-28 Bcn Peptides, S.A. Formulación tópica oftálmica de péptidos.
TWI605814B (zh) * 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽
JP5222917B2 (ja) * 2010-09-21 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
TWI501781B (zh) * 2010-12-10 2015-10-01 Ind Tech Res Inst 可控制釋放的組合物及其製造方法
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190117573A1 (en) * 2017-10-19 2019-04-25 Hyalo Technologies, LLC Composition and method of preparation of risperidone extended release preparation
US20230062487A1 (en) * 2020-01-24 2023-03-02 W. L. Gore & Associates, Inc. Sustained-release matrices for adventitial or periadventitial neural ablation and uses thereof
CN111643483B (zh) * 2020-07-06 2022-03-29 济南大学 一种用于制备加兰他敏缓释微球的方法
CA3210098A1 (en) 2021-02-24 2022-09-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
WO2022226534A2 (en) * 2021-04-23 2022-10-27 Oakwood Laboratories, Llc Microsphere formulations comprising multiple non-identical peptides and methods for making the same
JP7779583B2 (ja) * 2021-11-18 2025-12-03 インベンテージ ラボ インコーポレイテッド 難溶性薬物を含むマイクロ粒子の製造方法
US20250009644A1 (en) * 2021-12-02 2025-01-09 University Of Connecticut Long-acting injectable in situ forming biodegradable implants comprising non-steroidal anti-inflammatory drugs
CN116421578A (zh) * 2023-03-31 2023-07-14 辉粒药业(苏州)有限公司 生长抑素类似物缓释微球及其制备方法
JP2026513824A (ja) * 2023-04-03 2026-05-01 フェリング ベスローテン フェンノートシャップ ペプチド塩を製造する方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
US3664963A (en) * 1969-10-22 1972-05-23 Balchem Corp Encapsulation process
DE2059494B2 (de) * 1970-12-03 1972-03-16 Licentia Gmbh Biegsamer hohlleiter
JPS523342B2 (enExample) * 1972-01-26 1977-01-27
US3865352A (en) * 1973-11-16 1975-02-11 Minnesota Mining & Mfg Static mixing device
DE2604832A1 (de) * 1976-02-07 1977-08-11 Basf Ag Verfahren zur analyse von loesungen
US4171981A (en) * 1977-04-29 1979-10-23 The Mead Corporation Process for the production of hot melt coating compositions containing microcapsules
US4183681A (en) * 1978-05-19 1980-01-15 Exxon Research & Engineering Co. Emulsion preparation method using a packed tube emulsifier
US4299501A (en) * 1979-08-10 1981-11-10 Ortho Pharmaceutical Corporation Continuous process for the preparation of semisolid dispersions
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4933105A (en) * 1980-06-13 1990-06-12 Sandoz Pharm. Corp. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3732370A1 (de) 1987-09-25 1989-04-06 Hoechst Ag Verfahren zur vermischung von lebenden zellen oder mikroorganismen mit einer viskosen fluessigkeit und mischungen, die nach diesem verfahren hergestellt wurden
WO1990013361A1 (en) * 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6120805A (en) * 1990-04-06 2000-09-19 Rhone-Poulenc Rorer Sa Microspheres, process for their preparation and their use
FR2660556B1 (fr) 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
NZ260909A (en) * 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
ATE212830T1 (de) * 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
JP2832143B2 (ja) * 1993-12-28 1998-12-02 信越化学工業株式会社 シリコーン微粒子およびその製造方法
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US5629277A (en) * 1995-10-04 1997-05-13 William L. Brown Paint removing composition
US6140040A (en) * 1995-10-06 2000-10-31 Advanced Minerals Corporation Method of mechanically separating microparticles suspended in fluids using particulate media
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO1998032423A1 (en) * 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
JPH10273447A (ja) 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
SE9701161D0 (sv) * 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
NZ505651A (en) * 1998-01-16 2003-08-29 Takeda Chemical Industries Ltd Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer
US6270700B1 (en) * 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
JP3012608B1 (ja) * 1998-09-17 2000-02-28 農林水産省食品総合研究所長 マイクロチャネル装置及び同装置を用いたエマルションの製造方法
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2001027165A1 (en) * 1999-10-08 2001-04-19 The Procter & Gamble Company APPARATUS AND PROCESS FOR IN-LINE PREPARATION OF HIPEs
AUPQ529000A0 (en) * 2000-01-28 2000-02-17 Research Laboratories Of Australia Pty Ltd Toner characterization cell
US6953593B2 (en) * 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
JP2002126043A (ja) * 2000-07-17 2002-05-08 Takeda Chem Ind Ltd 凍結乾燥物の製造法
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
EP2316490A3 (en) * 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
JP2004525403A (ja) 2001-01-15 2004-08-19 スリーエム イノベイティブ プロパティズ カンパニー 可視波長領域における透過が高く、かつ平滑な多層赤外反射フィルム、およびそれから製造される積層物品
WO2002058672A2 (en) 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
TW200526267A (en) * 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
WO2003092585A2 (en) 2002-05-02 2003-11-13 Pr Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
WO2004078147A2 (en) * 2003-03-05 2004-09-16 Pr Pharmaceuticals Oxytocin controlled release formulations and methods of using same
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
WO2005003180A2 (en) 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
US9040664B2 (en) 2003-04-11 2015-05-26 Antriabio, Inc. Materials and methods for preparing protein-polymer conjugates
AU2004259208B2 (en) 2003-07-15 2011-04-28 Evonik Corporation Method for the preparation of controlled release formulations
AU2004259209A1 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions

Also Published As

Publication number Publication date
CN1852687B (zh) 2014-01-22
AU2004259208A1 (en) 2005-02-03
EP1651136A4 (en) 2009-07-08
EP2462896A1 (en) 2012-06-13
US8871269B2 (en) 2014-10-28
AU2004259208B2 (en) 2011-04-28
JP2007524645A (ja) 2007-08-30
ES2625343T3 (es) 2017-07-19
CA2532302A1 (en) 2005-02-03
CN1852687A (zh) 2006-10-25
JP5165239B2 (ja) 2013-03-21
EP1651136B1 (en) 2017-03-08
CN102935069A (zh) 2013-02-20
US20060228414A1 (en) 2006-10-12
BRPI0412059A (pt) 2006-09-05
WO2005009356A2 (en) 2005-02-03
WO2005009356A3 (en) 2005-06-09
JP2011144207A (ja) 2011-07-28
EP1651136A2 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
US8871269B2 (en) Method for the preparation of controlled release formulations
CA2533592C (en) Controlled release compositions
AU2004277419B2 (en) Nanoparticulate therapeutic biologically active agents
EP0766554B1 (en) Polymer microparticles for drug delivery
EP1742616B1 (en) Sustained-release microspheres and methods of making and using same
AU2002320441A1 (en) A controlled release biodegradable gel matrix
Sinha et al. Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres
HK1217912A1 (en) Controlled-released peptide formulations
HK1172231A (en) Method for the preparation of controlled release formulations
HK1170411A (en) Controlled release compositions
HK1181681A (en) Method for the preparation of controlled release formulations

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190715